Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Avior Wealth Management LLC

Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 138.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 530 shares of the medical research company’s stock after buying an additional 308 shares during the period. Avior Wealth Management LLC’s holdings in Edwards Lifesciences were worth $35,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp lifted its position in Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares in the last quarter. AustralianSuper Pty Ltd lifted its holdings in shares of Edwards Lifesciences by 17.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares in the last quarter. Ownership Capital B.V. lifted its holdings in shares of Edwards Lifesciences by 1.2% during the 3rd quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock valued at $197,509,000 after acquiring an additional 34,597 shares in the last quarter. American Century Companies Inc. boosted its position in Edwards Lifesciences by 2.1% during the 2nd quarter. American Century Companies Inc. now owns 2,082,961 shares of the medical research company’s stock worth $192,403,000 after purchasing an additional 43,247 shares during the period. Finally, Raymond James & Associates increased its holdings in Edwards Lifesciences by 2.8% in the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock valued at $168,597,000 after purchasing an additional 50,124 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Citigroup reduced their price objective on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, October 1st. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. UBS Group dropped their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Royal Bank of Canada decreased their target price on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Price Performance

Shares of EW opened at $71.26 on Tuesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a fifty day moving average price of $67.74 and a 200 day moving average price of $75.48. The company has a market cap of $42.03 billion, a P/E ratio of 10.28, a PEG ratio of 3.96 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 EPS. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,000 shares of company stock worth $2,657,000. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.